ProSci

Rat TNFRSF17/BCMA/CD269 Recombinant Protein (85-902)

Product Code:
PSI-85-902
Product Group:
Recombinant Proteins
Supplier:
ProSci
Regulatory Status:
RUO
Target Species:
Rat
Applications:
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Immunogen
  • SDS-PAGE
  • Western Blot (WB)
Product Types:
  • CD Proteins
  • Receptors
Shipping:
RT
Storage:
Store at -20°C. Store the lyophilized protein at -20°C to -80 °C up to 1 year from the date of receipt. After reconstitution, the protein solution is stable at -20°C for 3 months, at 2-8°C for up to 1 week.
 

No additional charges, what you see is what you pay! *

Show prices   How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges to UK mainland customers, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • Show All

Further Information

Application Note:
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity Test
Background:
Tumor necrosis factor receptor superfamily, member 17 (TNFRSF17), also known as B cell maturation antigen (BCMA) or CD269 antigen, is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature Blymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13BBAFF), and to lead to NF kappaB and MAPK8/JNK activation. TNFRSF17/BCMA/CD269 also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. TNFRSF17/BCMA/CD269 is a receptor for TALL-1 and BCMA activates NF-kappaB through a TRAF5-, TRAF6-, NIK-, and IKK-dependent pathway. The identification of TNFRSF17 as a NF-kappaB-activating receptor for TALL-1 suggests molecular targets for drug development against certain immunodeficient or autoimmune diseases. TNFRSF17/BCMA is a target of donor B-cell immunity in patients with myeloma who respond to DLI. Antibody responses to cell-surface BCMA may contribute directly to tumor rejection in vivo.
Buffer:
Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
NCBI Gene ID:
287034
Physical State:
Lyophilized
Predicted MW:
31.52 kDa
Protein Accession:
NP_001099231.1
Source Species:
HEK293 cells
SwissProt:
D3ZKQ8

Documents